INVESTORS CAREERS RESOURCES Press Press release Biotech 04/11/2021 ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia Read more Corporate Financial 25/10/2021 Oncodesign has appointed Karine Lignel as Group Chief Development Officer Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel. Read more Biotech 21/10/2021 Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. Read more Financial 16/09/2021 Oncodesign announces its results for the first half of 2021 Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence. Read more Financial 21/07/2021 Oncodesign announces a sharp increase in turnover in the first half of 2021 Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel... Read more Corporate Financial 05/07/2021 Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director. Read more Service 01/07/2021 Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials. Read more Service Financial 28/06/2021 Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO [Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers. Biotech Financial 24/06/2021 Oncodesign provides an update on its progress on RIPK2 [Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix. Read more Financial 18/06/2021 Oncodesign maintains its revenue and operating income at €38 million in 2020… [Press Release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis Read more Biotech 14/06/2021 Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease. Read more A.I Financial 18/05/2021 InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI. Read more 1 2 … 6 7 Contact-us 18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260 Get in touch Science within easy reach! Receive our general letter or our financial news! Explore Oncodesign's vitality Legal notice Personal data policy